Ascendis Pharma A/S (ASND) is moving higher as investors react to a corporate listing-structure update: the company said it plans to list its ordinary shares directly on Nasdaq effective at the opening of trading on April 20, 2026. As part of the transition, the existing American Depositary Shares (ADS) will be mandatorily exchanged into ordinary shares that are expected to trade under the ticker “ASND” on the Nasdaq Global Select Market.

A shift away from an ADS program to a direct ordinary-share listing can reduce the “wrapper” complexity for some investors and may improve trading efficiency over time, particularly for institutions that prefer holding ordinary shares instead of depositary receipts. The announcement can also act as a near-term catalyst because it forces operational repositioning by some holders (and sometimes by stock-loan/short participants) ahead of a hard effective date.

Key near-term watch items include broker communications on the mandatory exchange mechanics, any temporary trading/settlement frictions as positions convert, and whether options/stock-loan markets reprice around the April 20, 2026 effective date. Separately, investors will be focused on the next major company updates, including the next scheduled earnings timeframe shown by market calendars.